Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company targeting the healthcare and domestic pharmaceutical manufacturing sector. The SPAC filed a Form 10-Q with the SEC on August 14, 2025, indicating it remains in the search phase of its acquisition process. As its name suggests, DMAA was formed with a strategic focus on companies involved in U.S.-based drug production and pharmaceutical supply-chain infrastructure, a sector that has drawn increased investor attention amid ongoing policy discussions around domestic medicine manufacturing. For complete filings, sponsor details, deal timelines, and real-time status updates on DMAA, sign up for full data access at SpacDesk.